passage bio stock price
102 rows Discover historical prices for PASG stock on Yahoo Finance. Black Diamond Therapeutics Inc 154 BDTX253 Finch Therapeutics Group Inc 154 FNCH1407 Orchard Therapeutics PLC - ADR 044 ORTX162 Verastem Inc 030.
Quotes Snapshot PASG.
. Free current stock price quotes and data for Passage Bio Inc PASG. Research news charts stock market performance and earnings. The Closing Price Intraday High Intraday Low and Volume have been adjusted to account for any stock splits andor dividends that may have occurred for this.
According to analysts consensus price target of 1320 Passage Bio has a forecasted upside of 9076 from its current price of 131. Is a genetic medicines company. Passage Bio Inc 130 001 076 Watch.
View daily weekly or monthly format back to when Passage Bio Inc. A high-level overview of Passage Bio Inc. Passage Bio Inc.
Stay up to date on the latest stock price chart news analysis fundamentals trading and investment tools. The latest price target for. The stocks lowest day price was 203.
Passage Bio stock price target cut to 9 from 16 at Wedbush. According to the issued ratings of 6 analysts in the last year the consensus rating for Passage Bio stock is Moderate Buy based on the current 2 hold ratings and 4 buy ratings. Get Passage Bio stock.
PASG was reported by Citigroup on Tuesday May 17 2022The analyst firm set a price target for 1000 expecting. Passage Bio is trading at 222 as of the 3rd of June 2022 a 829 percent increase since the beginning of the trading day. Cmta Star Biotech Alliance Partners PASG stock price quote stock graph news analysis.
PASG Stock Price Prediction 1450 103281 Upside Based on 3 Wall Street analysts offering 12 month price targets for Passage Bio in the last 3 months. Find real-time PASG - Passage Bio Inc stock quotes company profile news and forecasts from CNN Business. Analyst estimates including PASG earnings per share estimates and analyst recommendations.
It is focused on developing transformative therapies for rare monogenic central nervous system diseases. The 12-month stock price forecast is 976 which is an increase of 64504 from the latest price. Passage Bio Inc Shares Near 52-Week Low - Market Mover Kwhen Jan 23 2022 See All News About Passage Bio Inc.
2005 MARKET STREET 39TH FLOOR ONE COMMERCE. The average price target is. Find the latest Passage Bio Inc.
PASG stock quote history news and other vital information to help you with your stock trading and investing. No competitors data available. Not an offer or recommendation by Stocktwits.
Price Target 976 64504 upside Analyst Consensus. 619a Ambarella stock price target cut to 100 from 120 at KeyBanc Capital. Passage Bio Inc NASDAQ Updated Oct.
Passage Bio Inc. Amount of Analyst Coverage. Stay up to date on the.
Closing Price 136 NOTE. Company facts information and financial ratios from MarketWatch. The 11 analysts offering price forecasts for Passage Bio have a median target of 2427 with a high estimate of 4500 and a low estimate of 600.
Passage Bio Stock Pasg Price Reduced But Without Data Does Not Look Convincing Seeking Alpha
Passage Bio Company Profile Stock Performance Earnings Pitchbook
Why The Day One Ipo Pop Is Overhyped Marker
Pasg Passage Bio Inc Stock Price Quote Nasdaq Gs Bloomberg
Dx Stocks Rise In July Led By Natera Invitae 360dx
Surviving Biotech S Longest And Steepest Bear Market Ever
Sofi Stock Breaking Down The Bear Case Nasdaq Sofi Seeking Alpha
Passage Bio Stock Quote Pasg Stock Price News Charts Message Board Trades
Passage Bio Pulls Off 216m Ipo Blowing Past Original Goal Fierce Biotech
Amazon Com The Passage Of Power The Years Of Lyndon Johnson Vol Iv 9780375713255 Caro Robert A Books
Passage Bio Inc Investors And News Stock Information
Pasg Institutional Ownership And Shareholders Passage Bio Inc Nasdaq Stock
Chemomab Therapeutics Nasdaqcm Cmmb Stock Price Quote Analysis Simply Wall St
Time To Go Bottom Fishing These 3 Strong Buy Stocks Are On Sale Nasdaq
What Is China Doing To Its Stock Market And Why A Hypothesis Nasdaq
Stock Trades Reported By Nearly A Fifth Of Congress Show Possible Conflicts The New York Times
Gene Therapy Developer Passage Bio Files For 125m Ipo
The Growth Potential Of Psychedelics Stocks And Etfs Seeking Alpha